GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Radiopharm Theranostics RAD.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.00

0.00%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Radiopharm Theranostics — daily ASX:RAD

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Radiopharm Theranostics on TradingView ↗
Market value
A$8.7m
Last close × shares
Volume
26.1m
Shares, 9 Nov 2026

About Radiopharm Theranostics

Its shares trade on ASX under the ticker RAD.AX. It has been listed since 25 November 2021. In the fiscal year to 30 June 2026, it reported revenue of A$2.8m and a net loss of A$55.1m. At that date it held total assets of A$60.1m and shareholders' equity of A$24.7m.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The firm has a pipeline of six platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including breast, kidney and brain. The firm's technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labeled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

Figures and description from our data supplier, not checked against the company's own report.

More about Radiopharm Theranostics →

Latest on Radiopharm Theranostics

Our reporting

Next results

26 Feb 2027

Due on 26 Feb 2027. Analysts expect earnings of -0.01 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Radiopharm Theranostics's ticker?

Radiopharm Theranostics trades as RAD.AX on ASX, under ISIN AU0000181851.

What was Radiopharm Theranostics's last closing price?

0.00 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Radiopharm Theranostics next report results?

Results are expected on 26 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.